Valerio Therapeutics (XPAR:ALVIO) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 09, 2026)


XPAR:ALVIO Valerio Therapeutics XPAR:ALVIO
28 GF Score
Price €0.46
GF Value €0.07
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Valerio Therapeutics Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Valerio Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

XPAR:ALVIO vs VRTX, REGN, ALNY: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Valerio Therapeutics's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valerio Therapeutics Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Valerio Therapeutics's Margin of Safety % (DCF Dividends Based) falls into.


XPAR:ALVIO
28GF Score
Valerio Therapeutics XPAR:ALVIO
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Valerio Therapeutics (XPAR:ALVIO) Overvalued in 2026?

Based on GuruFocus' analysis, Valerio Therapeutics stock appears to be overvalued. The current stock price of €0.46 is trading 550% above its estimated GF Value™ of €0.07. GuruFocus considers Valerio Therapeutics to be Significantly Overvalued.

Key valuation signals for XPAR:ALVIO:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: €0.07 vs. price of €0.46 (550% above fair value)
  • GF Score™: 28/100 with 9 warning signs

No single metric tells the full story. See the XPAR:ALVIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valerio Therapeutics Business Description

Other Exchanges 0NWK:UKC4X:Germany
Address 49, Boulevard du General, Martial Valin, Paris, FRA, 75015
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
28GF Score

Get the complete analysis for XPAR:ALVIO

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.46
Price
€0.07
GF Value